Organon & Co. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Organon & Co. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.22B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $6.40B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $6.26B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $6.17B | Nov 10, 2025 |
| FY2023 | Dec 31, 2021 | $6.30B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $6.53B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $7.78B | Mar 21, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.31B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.72B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $3.75B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $3.88B | Nov 10, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $864.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.02B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $917.00M | Nov 10, 2025 |
| FY2023 | Dec 31, 2021 | $1.35B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $2.16B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $3.22B | Mar 21, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $443.00M | Mar 21, 2022 |
| FY2021 | Dec 31, 2020 | $210.00M | Mar 21, 2022 |
| FY2021 | Dec 31, 2019 | $220.00M | Mar 21, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.72B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.76B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.89B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.70B | Nov 10, 2025 |
| FY2023 | Dec 31, 2021 | $1.67B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.36B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.44B | Mar 21, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $700.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $939.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $799.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $858.00M | Nov 10, 2025 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $162.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $175.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $251.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $196.00M | Nov 10, 2025 |
| FY2023 | Dec 31, 2021 | $192.00M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $255.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $92.00M | Mar 21, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.87B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $13.10B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $12.06B | Nov 10, 2025 |
| FY2023 | Dec 31, 2022 | $10.96B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $10.68B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $10.11B | Mar 21, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.12B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $12.63B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $12.13B | Nov 10, 2025 |
| FY2023 | Dec 31, 2022 | $11.85B | Feb 26, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $752.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $472.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($70.00M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | ($892.00M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | ($1.51B) | Nov 10, 2025 |
| FY2023 | Dec 31, 2020 | $5.49B | Feb 26, 2024 |
| FY2022 | Dec 31, 2019 | $7.04B | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $6.35B | Mar 21, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.15B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.68B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $4.60B | Feb 24, 2026 |
| FY2023 | Dec 31, 2022 | $4.60B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $4.60B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $4.60B | Mar 21, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $443.00M | Nov 10, 2025 |
| FY2023 | Dec 31, 2022 | ($331.00M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($998.00M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 21, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $574.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $675.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $693.00M | Nov 10, 2025 |
| FY2023 | Dec 31, 2022 | $706.00M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $737.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $12.00M | Mar 21, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.64B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $8.88B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $8.76B | Nov 10, 2025 |
| FY2023 | Dec 31, 2022 | $8.91B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $9.13B | Feb 27, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Nov 10, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 8 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 12 | Mar 21, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Nov 10, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 8 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 12 | Mar 21, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 260.32M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 257.80M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 255.63M | Nov 10, 2025 |
| FY2023 | Dec 31, 2022 | 254.37M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 253.55M | Feb 27, 2023 |